Preparing Families for Influenza Season: The Latest Diagnosis, Treatment, and Prophylaxis Strategies

Preparing Families for Influenza Season: The Latest Diagnosis, Treatment, and Prophylaxis Strategies

Online Course | Specialties: Family Medicine, Pediatrics, Primary Care
Released: 10/29/2020
Expires: 10/28/2021
Max Credits: 0.5
Jump to Education

Paul G. Auwaerter, MD
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Kathryn Birken-Friedman, MD
Doctor of Pediatric Emergency Medicine
Joe DiMaggio Children's Hospital
Hollywood, FL

John J. Russell, MD, FAAFP
Clinical Professor, Family and Community Medicine
Sydney Kimmel Medical College
Thomas Jefferson University School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Director, Family Medicine Residency Program
Abington Hospital – Jefferson Health
Abington, PA

Activity Planners
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
East Lansing, MI

Amy Sison
Director of CME
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Identify individuals who may benefit from antiviral therapies for influenza treatment or prophylaxis
  • Evaluate available and emerging antivirals in terms of safety, efficacy, mechanism of action, dosing, outcomes, and role within the influenza management and prevention paradigms
  • Incorporate effective education and communication strategies into personalized influenza treatment plans for pediatric patients and their families

Target Audience
This activity is intended for physicians, physician assistants, nurse practitioners, and nurses in pediatrics and family medicine.

Statement of Need
Influenza causes significant morbidity and mortality creating a serious burden on children and their families, particularly among younger children who may have a high risk of complications. Delays in seeking medical care and diagnosis limit the opportunity to employ critical antiviral treatments and prevention strategies, consequently placing infected children at risk of potentially life-threatening complications and their families at risk of further infection. The continuous evolution of the influenza virus paired with suboptimal vaccination rates and vaccine efficacy underscore the need for antiviral therapies. The evolving data for current and emerging treatments, the recent approval of a novel antiviral, and limited guidance on influenza treatment create a challenging environment for providers to optimally incorporate the latest advances into influenza treatment and prevention plans. Primary care clinicians need to know the benefits, risks, and characteristics of available and emerging agents for influenza treatment and prophylaxis. Primary care clinicians should also be able to enhance parent/caregiver-provider relationships and support productive and evidence-based discussions surrounding the treatment of pediatric influenza and related prophylaxis.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 0.5 contact hour.

Physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
To receive credit, read the introductory CME/CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: October 29, 2020
Expiration Date: October 28, 2021
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Paul G. Auwaerter, MD
Ownership interest (stocks/stock options – excluding mutual funds): Johnson & Johnson

Kathryn Birken-Friedman, MD, has indicated no real or apparent conflicts.

John J. Russell, MD, FAAFP
Consulting fees/advisory boards: GlaxoSmithKline, Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CME activities: Sanofi-aventis U.S. Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.

© 2020 Med-IQ, Inc.


Here are some key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available by clicking the "Continue" button below.

  • Flu can cause mild-to-severe illness and, at times, can lead to death
  • Approximately 6% to 12% of children see a healthcare professional for influenza-related illness each year
  • Approximately 41% of children with influenza experience flu-related complications such as pneumonia, seizures, other secondary bacterial infections such as sinusitis or otitis media, and exacerbation of existing respiratory issues such as asthma
  • Children younger than 5 years are considered to have a high risk of experiencing influenza complications
  • There are similarities and differences in the symptom presentation between influenza, COVID-19, and the common cold. The flu can come on suddenly with symptoms such as high fever, chills, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, and tiredness, and some individuals may experience vomiting and diarrhea
  • Patients who are at high risk of flu complications include children younger than 5 years, adults older than 65 years, pregnant women, American Indians, Alaska Natives, people with obesity, and people with weakened immune systems, as well as other comorbidities
  • Clinicians should consider early empiric antiviral treatment of non-high-risk outpatients with suspected influenza and treatment should ideally be initiated within 48 hours of illness onset
  • Delays in seeking medical care and diagnosis limit the opportunity to employ critical antiviral treatments and prevention strategies, consequently placing infected children at risk for potentially life-threatening complications and their families at risk of contracting influenza
  • Currently there are 4 antiviral treatments approved by the FDA: baloxavir, oseltamivir, peramivir, and zanamivir. Differences in MOA, indications, dosing/administrations, safety, and efficacy should be considered
  • Clinicians can consider short-term antiviral chemoprophylaxis for unvaccinated adults and for children 3 months and older who are in close contact with persons at high risk of developing influenza complications
  • Most of the antiviral treatments are approved to be used as chemoprophylaxis with additional antiviral treatments currently under investigation

View reference list.

Click "Continue" to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the chapters in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.